title: Comparison of the effects of zaleplon, zolpidem, and triazolam on memory, learning, and psychomotor performance.
abstract: Twenty-four healthy male and female subjects, who participated in this randomized, double-blind, crossover study, received single nighttime doses of zaleplon 10 mg (therapeutic dose), zaleplon 20 mg, zolpidem 10 mg (therapeutic dose), zolpidem 20 mg, triazolam 0.25 mg (positive control), and placebo. Subjective behavioral ratings and psychomotor tests were completed before and 1.25 and 8.25 hours after administration of the study drug. The Immediate and Delayed Word Recall tests and the Digit Span Test were used to assess memory. The Digit-Symbol Substitution Test, Paired Associates Learning Test, and Divided Attention Test were used to assess other cognitive skills. Zaleplon 10 mg did not produce any significant changes in memory or learning compared with placebo. All other active treatments, including zolpidem 10 mg, caused psychomotor impairment at the 1.25-hour test battery. Zolpidem 20 mg (twice the therapeutic dose) produced more psychomotor impairment at the 1.25-hour assessment than did any of the other active treatments, including zaleplon 20 mg. At the 8.25-hour time point, test scores for subjects who received zaleplon 10 mg and 20 mg did not differ from the test scores for those who received placebo. However, cognitive impairment persisted up to the 8.25-hour observation for subjects who were administered triazolam 0.25 mg and zolpidem 20 mg. Adverse events associated with the use of zaleplon were transient and mild-to-moderate in severity. Overall, this study shows that zaleplon is a safe hypnotic that does not affect memory, learning, or psychomotor skills associated with vigilance.
authors.affiliation: Wyeth-Ayerst Research, Radnor, Pennsylvania 19087, USA. troys@war.wyeth.com
authors.forename: S M
authors.initials: SM
authors.lastname: Troy
authors.forename: I
authors.initials: I
authors.lastname: Lucki
authors.forename: M A
authors.initials: MA
authors.lastname: Unruh
authors.forename: W H
authors.initials: WH
authors.lastname: Cevallos
authors.forename: C A
authors.initials: CA
authors.lastname: Leister
authors.forename: P T
authors.initials: PT
authors.lastname: Martin
authors.forename: P M
authors.initials: PM
authors.lastname: Furlan
authors.forename: R
authors.initials: R
authors.lastname: Mangano
mesh_terms: D000081:Acetamides / Q000009:adverse effects / Q000494:pharmacology*; D000293:Adolescent; D000328:Adult; D000339:Affect / Q000187:drug effects; D001245:Association Learning / Q000187:drug effects; D001288:Attention / Q000187:drug effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects / Q000494:pharmacology*; D007858:Learning / Q000187:drug effects*; D008297:Male; D008568:Memory / Q000187:drug effects*; D011939:Mental Recall / Q000187:drug effects; D008875:Middle Aged; D011597:Psychomotor Performance / Q000187:drug effects*; D011725:Pyridines / Q000009:adverse effects / Q000494:pharmacology*; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology*; D012727:Sex Characteristics; D011795:Surveys and Questionnaires; D014229:Triazolam / Q000009:adverse effects / Q000494:pharmacology*; D000077334:Zolpidem
chemical_list: D000081:Acetamides; D006993:Hypnotics and Sedatives; D011725:Pyridines; D011743:Pyrimidines; D014229:Triazolam; D000077334:Zolpidem; C085665:zaleplon